Cytox Limited

Cytox Limited is a biotechnology startup based in the United Kingdom that is focused on defining genetic risk for dementia. Founded in 2004, the company's mission is to enable individuals to assess their personal risk for Alzheimer's disease. Cytox has developed the genoSCORE™ technology, which utilizes over 100,000 bits of DNA to compute an individual's genetic risk of developing Alzheimer's disease as a single risk score. The company's technology forms the basis of a Polygenic Risk Score test for Alzheimer's disease, which is currently available in the US and the UK. In the US, the Alzheimer’s Risk Test is offered by Sampled SMART Labs (www.Sampled.com), utilizing the genoSCORE™ technology provided by Cytox. In the UK, information about the test can be found at www.genoscore-lab.com. Cytox's offering of genetic testing provides individuals with insights into the significance of taking action to minimize the likelihood of developing Alzheimer's disease, as it emphasizes that genetic risk alone is not the sole determining factor. The test results can serve as motivation for making lifestyle adjustments, ultimately empowering individuals to manage their risk. The most recent investment of €71.43K grant was secured on 01 January 2019 from EASME - EU Executive Agency for SMEs.